{
    "clinical_study": {
        "@rank": "88931", 
        "arm_group": [
            {
                "arm_group_label": "Sugammadex (tradename Bridion)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Traditional reversal or spontaneous recovery:", 
                "arm_group_type": "Active Comparator", 
                "description": "Atropine/Neostigmine: Atropine, 0.02 mg/ kg, and Neostigmine,0.05 mg/kg diluted in 100 ml Normal Saline and given over a 10 min drip. Reversal will be given only recommended if spontaneous recovery has occurred up to the reappearance of T2 (shallow blockade) following rocuronium induced blockade."
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate that the use of Sugammadex enables physicians to perform early extubation in\n      the operating room in ASA 4 & 4E patients\n\n      Primary endpoint:\n\n      \u2022 Extubation in the operating room before transfer to the PACU or ICU versus keeping the\n      patient intubated when transferred.\n\n      Secondary endpoints:\n\n      \u2022 Time to extubation - measure the difference in time from application of the surgical\n      dressing until extubation. Atelectasis - comparison of chest x-rays (CXR): prior to surgery,\n      on admission to PACU or ICU and 24 hours after admission to PACU or ICU (This is the routine\n      practice at Hadassa hospital for ASA IV patients.)"
        }, 
        "brief_title": "A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients", 
        "condition": "Neuromuscular Blockade", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ASA 4 AND ASA 4E patients\n\n          -  Patients scheduled to undergo any bowel, urogenital or orthopedic surgery under\n             general anesthesia where use of neuromuscular blocking agents is indicated. -\n\n        Exclusion Criteria:\n\n          -  Patients ASA 1-3 or 5\n\n          -  Patients who have a medical condition which precludes extubation at the end of\n             surgery (i.e., mesenteric event, severe hypothermia etc.).\n\n          -  Presence of an advanced directive to withhold or withdraw life sustaining treatment\n             (i.e. DNR).\n\n          -  Hypersensitivity to the active substances or to any of the excipients of medications\n             used\n\n          -  Patients with severe renal impairment (including patients requiring dialysis (CrCl <\n             30mL/min))\n\n          -  Patients with severe hepatic impairment\n\n          -  Age < 18 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761552", 
            "org_study_id": "0513-12-HMO"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sugammadex (tradename Bridion)", 
                "intervention_name": "Sugammadex Reversal", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Traditional reversal or spontaneous recovery:", 
                "intervention_name": "Atropine/Neostigmine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atropine", 
                "Neostigmine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "in ASA 4 AND ASA 4E patients", 
        "lastchanged_date": "September 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel", 
                    "zip": "91120"
                }, 
                "name": "Hadassah Medical Organization"
            }, 
            "investigator": {
                "last_name": "Yoram Weiss, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients.", 
        "other_outcome": {
            "measure": "The effect of Sugammadex on cortisol levels", 
            "safety_issue": "Yes", 
            "time_frame": "72 hours"
        }, 
        "overall_contact": {
            "email": "lhadas@hadassah.org.il", 
            "last_name": "Hadas Lemberg, PhD", 
            "phone": "00 972 2 6777572"
        }, 
        "overall_official": {
            "affiliation": "Hadassah Medical Organization", 
            "last_name": "Yoram G Weiss, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Israeli Health Ministry Pharmaceutical Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Extubation in the operating room before transfer to the PACU or ICU versus keeping the patient intubated when transferred.", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to extubation - measure the difference in time from application of the surgical dressing until extubation.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Atelectasis - comparison of chest x-rays (CXR): prior to surgery, on admission to PACU or ICU and 24 hours after admission to PACU or ICU (This is the routine practice at Hadassa hospital for ASA IV patients.)", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Hadassah Medical Organization", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hadassah Medical Organization", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}